News

This is said to be the third Oradur-based opioid drug candidate covered by Durect’s collaboration with Pain Therapeutics, for which King Pharmaceuticals holds the commercialization rights. Pain Therapeutics

Under the terms of NIR Diagnostics’s settlement with Masimo, as with the Shaklee-Masimo settlement that preceded it, the case has been dismissed without either party incurring financial liability

Greyson intends to enter the royalty division of business and effectively license Trilexon to clients in the drug, cosmetic and toiletry industries, upon which Greyson will retain a

According to MedEfficiency, the TCC-EZ cast will act as a protective barrier for the open wounds that often develop on the undersides of diabetic patients’ feet, and help

Of 50 compounds identified, SF2523 and SF2506 have been chosen for additional evaluation based on their ability to inhibit multiple kinases, including PI3K, mTOR, DNA-PK and PIM-1. Evaluation

The company ended the trial as recommended by its independent data monitoring committee (IDMC) which observed an imbalance in deaths between the two treatment arms of the study.

Investors in the first closing of the private placement purchased 1.86 million shares of the company’s common stock at a price of $1.25 per share and received a

Pre-clinical studies have shown that Davanat, in combination with chemotherapy, significantly reduced tumor growth in mice implanted with metastatic human breast cancer. Results from similar pre-clinical studies designed

Dr Dolecek is currently Sucampo’s senior vice president of R&D. Dr Dolecek has received his BS from the University of Maryland and a MPH in health services and